ORAL VERSUS IV GANCICLOVIR IN CYTOMEGALOVIRUS RETINITIS

口服与 IV 更昔洛韦治疗巨细胞病毒性视网膜炎

• 批准号: 6415350
• 负责人: DANIEL F MARTIN
• 金额: $ 29.31万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-12-01 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6415350
• 关键词: clinical research; clinical trial phase I; cytomegalovirus; dosage; eye disorder chemotherapy; ganciclovir; human subject; human therapy evaluation; injection /infusion; intravenous administration; ocular herpes; oral administration; retinitis

This study seeks to determine whether RS79070 @900 mg BID and the recommended dose of IV gancyclovir @5 mg/kg BID for CMV retinitis will provide a convenient, safe and efficacious oral induction regimen in patients with CMV retinitis. As this is the first efficacy study with this formulation, the study population will be restricted to patients with newly diagnosed, nonsight-threatening peripheral CMV retinitis.

本研究旨在确定RS79070@900 mg BID和推荐剂量IV更昔洛韦@5 mg/kg BID治疗CMV视网膜炎是否将为CMV视网膜炎患者提供方便、安全和有效的口服诱导方案。 由于这是该制剂的首次疗效研究，因此研究人群将限于新诊断的、不危及视力的外周CMV视网膜炎患者。